> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 2 Guerbet Group NDAs Withdrawn
- URL: https://www.fdaweb.com/2-guerbet-group-ndas-withdrawn/
- Published: 2017-04-25T12:00:00.000Z
- Updated: 2026-09-14T22:19:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138531

*Federal Register* notice: FDA is withdrawing approval of two NDAs held by Guerbet Group after being notified that the products were no longer marketed. The affected products are Hexabrix (ioxaglate meglumine and ioxaglate sodium) injection and Oxilan-300 and Oxilan-350 (ioxilan) injection. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-04-24/pdf/2017-08179.pdf?ref=fdaweb.com).